menu
    • menu
    [{"orgOrder":0,"company":"Janssen-Cilag","sponsor":"Argenx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Termination","leadProduct":"Cusatuzumab","moa":"CD70","graph1":"Oncology","graph2":"Phase II","graph3":"Janssen-Cilag","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Janssen-Cilag \/ Argenx","highestDevelopmentStatusID":"8","companyTruncated":"Janssen-Cilag \/ Argenx"},{"orgOrder":0,"company":"Janssen-Cilag","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Erdafitinib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Janssen-Cilag","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Janssen-Cilag \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Janssen-Cilag \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Janssen-Cilag

    Menu

    Janssen-Cilag

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Janssen-Cilag

                            Italy arrow
                            Fi Europe 2024
                            Not Confirmed

                            Janssen-Cilag

                            Italy arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Erdafitinib

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            European Commission Approves BALVERSA for Metastatic Urothelial Carcinoma

                            Details : Balversa (erdafitinib) is a once-daily, oral FGFR kinase inhibitor approved for the treatment of adult patients with unresectable or metastatic urothelial carcinoma.

                            Brand Name : Balversa

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 23, 2024

                            Lead Product(s) : Erdafitinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Janssen-Cilag

                            Italy arrow
                            Fi Europe 2024
                            Not Confirmed

                            Janssen-Cilag

                            Italy arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cusatuzumab,Azacitidine

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Argenx

                            Deal Size : Undisclosed

                            Deal Type : Termination

                            DEALS_DEV arrow-down

                            Janssen Affiliate Cilag GmbH International Discontinues Collaboration and License Agreement with argenx for Cu...

                            Details : The decision is based upon Janssen's review of all available cusatuzumab data and in consideration of the evolving standard of care for the treatment of acute myeloid leukemia.

                            Brand Name : JNJ-74494550

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            June 07, 2021

                            Lead Product(s) : Cusatuzumab,Azacitidine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Argenx

                            Deal Size : Undisclosed

                            Deal Type : Termination

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth